Evidence-based recommendations on the E-vita open plus for treating complex aneurysms and dissections of the thoracic aorta.
In October 2018, this guidance was updated to include a review of the cost model using more recent values. New evidence and updated costs identified during the guidance review are denoted as .
To register as a stakeholder, contact us at firstname.lastname@example.org.
Next review: 2021
NICE medical technologies guidance addresses specific technologies notified to NICE by sponsors. The ‘case for adoption’ is based on the claimed advantages of introducing the specific technology compared with current management of the condition. This case is reviewed against the evidence submitted and expert advice. If the case for adopting the technology is supported, then the technology has been found to offer advantages to patients and the NHS. The specific recommendations on individual technologies are not intended to limit use of other relevant technologies which may offer similar advantages.